Improved statistical signal detection in pharmacovigilance by combining multiple strength-of-evidence aspects in vigiRank: Retrospective evaluation against emerging safety signals

Drug Safety

Volumn 37, Issue 8, 2014, Pages 617-628

  Caster, Ola ^a,b   Juhlin, Kristina ^a   Watson, Sarah ^a   Norén, G Niklas ^a,b  

^a UPPSALA MONITORING CENTRE   (Sweden)

^b STOCKHOLM UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ASSESSMENT; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; HUMAN; LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; SIGNAL DETECTION; STATISTICAL ANALYSIS; ALGORITHM; DRUG DATABASE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; PERCEPTIVE DISCRIMINATION; STATISTICAL MODEL;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ALGORITHMS; DATABASES, PHARMACEUTICAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; LOGISTIC MODELS; PHARMACOVIGILANCE; SIGNAL DETECTION, PSYCHOLOGICAL;

EID: 84906320834     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-014-0204-5     Document Type: Article

References (36)

1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta- analysis of prospective studies. J Am Med Assoc. 1998;279(15):1200-5. (Pubitemid 28193431)
2. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients. Br Med J. 2004;329(7456):15-9. (Pubitemid 38869995)
3. Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP. Adverse drug events in hospitalized patients: excess length of stay, extra costs, and attributable mortality. J Am Med Assoc. 1997;277(4):301-6. (Pubitemid 27045010)
4. Stricker BH, Psaty BM. Detection, verification, and quantification of adverse drug reactions. Br Med J. 2004;329(7456):44-7. (Pubitemid 38870007)
5. CIOMS Working Group XIII. Practical aspects of signal detection in pharmacovigilance. Geneva: CIOMS; 2010.
6. Wysowski DK, Swartz L. Adverse drug event surveillance and drug withdrawals in the united states, 1969-2002: the importance of reporting suspected reactions. Arch Intern Med. 2005;165(12):1363-9. (Pubitemid 40973418)
7. Vandenbroucke JP. In defense of case reports and case series. Ann Intern Med. 2001;134(4):330-4. (Pubitemid 32163956)
8. Coloma PM, Trifirò G, Schuemie MJ, Gini R, Herings R, Hippisley-Cox J, et al. Electronic healthcare databases for active drug safety surveillance: is there enough leverage? Pharmacoepidemiol Drug Saf. 2012;21(6):611-21.
9. van Puijenbroek EP, van Grootheest K, Diemont WL, Leufkens HG, Egberts AC. Determinants of signal selection in a spontaneous reporting system for adverse drug reactions. Br J Clin Pharmacol. 2001;52(5):579-86.
10. Ståhl M, Lindquist M, Edwards IR, Brown EG. Introducing triage logic as a new strategy for the detection of signals in the WHO drug monitoring database. Pharmacoepidemiol Drug Saf. 2004;13(6):355-63. (Pubitemid 38787154)
11. Waller P, Heeley E, Moseley J. Impact analysis of signals detected from spontaneous adverse drug reaction reporting data. Drug Saf. 2005;28(10):843-50. (Pubitemid 41428542)
12. Levitan B, Yee CL, Russo L, Bayney R, Thomas AP, Klincewicz SL. A model for decision support in signal triage. Drug Saf. 2008;31(9):727-35.
13. Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, Lansner A, et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol. 1998;54(4):315-21. (Pubitemid 28328016)
14. Evans SJW, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001;10(6):483-6. (Pubitemid 34100774)
15. DuMouchel W. Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system. Am Stat. 1999;53(3):177-90.
16. Hauben M, Madigan D, Gerrits CM, Walsh L, van Puijenbroek EP. The role of data mining in pharmacovigilance. Expert Opin Drug Saf. 2005;4(5):929-48. (Pubitemid 41246142)
17. Caster O, Norén GN, Madigan D, Bate A. Large-scale regression-based pattern discovery: the example of screening the WHO global drug safety database. Stat Anal Data Min. 2010;3(4):197-208.
18. Tatonetti NP, Ye PP, Daneshjou R, Altman RB. Data-driven prediction of drug effects and interactions. Sci Transl Med. 2012;4(125):125ra31.
19. Berlin C, Blanch C, Lewis DJ, Maladorno DD, Michel C, Petrin M, et al. Are all quantitative postmarketing signal detection methods equal? Performance characteristics of logistic regression and multi-item Gamma Poisson Shrinker. Pharmacoepidemiol Drug Saf. 2012;21(6):622-30.
20. Harpaz R, DuMouchel W, LePendu P, Bauer-Mehren A, Ryan P, Shah NH. Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system. Clin Pharmacol Ther. 2013;93(6):539-46.
21. Caster O, Norén GN, Madigan D, Bate A. Logistic regression in signal detection: another piece added to the puzzle. Clin Pharmacol Ther. 2013;94(3):312.
22. Van Holle L, Zeinoun Z, Bauchau V, Verstraeten T. Using time-to-onset for detecting safety signals in spontaneous reports of adverse events following immunization: a proof of concept study. Pharmacoepidemiol Drug Saf. 2012;21(6):603-10.
23. Edwards IR, Lindquist M, Wiholm BE, Napke E. Quality criteria for early signals of possible adverse drug reactions. Lancet. 1990;336(8708):156-8. (Pubitemid 20224982)
24. Strandell J, Caster O, Hopstadius J, Edwards IR, Norén GN. The development and evaluation of triage algorithms for early discovery of adverse drug interactions. Drug Saf. 2013;36(5):371-88.
25. Bergvall T, Norén GN, Lindquist M. vigiGrade: a tool to identify well-documented individual case reports and highlight systematic data quality issues. Drug Saf. 2014;37(1):65-77.
26. Norén GN, Hopstadius J, Bate A. Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery. Stat Methods Med Res. 2013;22(1):57-69.
27. Hopstadius J, Norén GN. Robust discovery of local patterns: Subsets and stratification in adverse drug reaction surveillance. In: Proceedings of the 2nd ACM SIGHIT International Health Informatics Symposium. ACM; Miami (FL); 2012:265-74.
28. Alvarez Y, Hidalgo A, Maignen F, Slattery J. Validation of statistical signal detection procedures in EudraVigilance post-authorization data: a retrospective evaluation of the potential for earlier signalling. Drug Saf. 2010;33(6):475-87.
29. Lindquist M. VigiBase, the WHO global ICSR database system: basic facts. Drug Inf J. 2008;42(5):409-19.
30. Norén GN, Orre R, Bate A, Edwards IR. Duplicate detection in adverse drug reaction surveillance. Data Min Knowl Discov. 2007;14(3):305-28. (Pubitemid 46582604)
31. Copas JB. Regression, prediction and shrinkage. J R Stat Soc Ser B Methodol. 1983;45(3):311-54.
32. Tibshirani R. Regression shrinkage and selection via the Lasso. J R Stat Soc Ser B Methodol. 1996;58(1):267-88.
33. Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. J Stat Softw. 2010;33(1):1-22.
34. Jahrer M, Töscher A, Legenstein R. Combining predictions for accurate recommender systems. In: Proceedings of the 16th ACM SIGKDD international conference on knowledge discovery and data mining. ACM; Washington, DC; 2010:693-702.
35. Hosmer DW, Lemeshow S. Applied logistic regression. New York: Wiley; 1989.
36. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44(3):837-45.